Wildcat Capital Management, LLC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 169 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 6.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
Wildcat Capital Management, LLC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$6,805,434
-13.6%
2,920,787
+52.1%
1.66%
-41.8%
Q1 2024$7,877,861
+27.8%
1,920,7870.0%2.86%
+34.1%
Q4 2023$6,165,726
+1.3%
1,920,7870.0%2.13%
-12.8%
Q3 2023$6,088,895
-36.2%
1,920,7870.0%2.44%
-32.7%
Q2 2023$9,546,311
+0.6%
1,920,7870.0%3.63%
+3.0%
Q1 2023$9,488,688
-29.1%
1,920,787
-9.8%
3.53%
-31.0%
Q4 2022$13,387,447
-41.8%
2,128,3700.0%5.11%
-42.1%
Q3 2022$22,986,000
-5.3%
2,128,3700.0%8.83%
+9.9%
Q2 2022$24,263,000
+25.1%
2,128,3700.0%8.04%
+62.0%
Q1 2022$19,389,000
-24.3%
2,128,370
+24.0%
4.96%
+19.0%
Q4 2021$25,608,000
-41.9%
1,716,3700.0%4.17%
-27.0%
Q3 2021$44,111,000
-1.5%
1,716,3700.0%5.71%
+12.4%
Q2 2021$44,763,000
-16.3%
1,716,370
+13.3%
5.08%
-22.3%
Q1 2021$53,498,000
+39.9%
1,515,5240.0%6.53%
+35.9%
Q4 2020$38,252,000
-33.1%
1,515,5240.0%4.81%
-73.7%
Q3 2020$57,150,000
-11.9%
1,515,5240.0%18.27%
-18.5%
Q2 2020$64,895,000
+147.3%
1,515,524
+12.3%
22.42%
+87.7%
Q1 2020$26,237,000
-16.0%
1,349,642
+12.3%
11.95%
+32.6%
Q4 2019$31,223,000
+26.4%
1,201,826
+32.6%
9.01%
-14.2%
Q3 2019$24,698,000
+72.8%
906,194
+70.3%
10.49%
+69.7%
Q2 2019$14,289,000532,1666.18%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$26,829,00010.04%
Wildcat Capital Management, LLC 1,716,370$25,608,0004.17%
TPG GP A, LLC 18,716,306$279,247,0002.79%
Casdin Capital, LLC 2,650,000$39,538,0001.11%
Lombard Odier Asset Management (Switzerland) SA 996,116$14,862,0000.95%
Coastal Bridge Advisors, LLC 301,929$4,505,0000.94%
HARBOR CAPITAL ADVISORS, INC. 119,547$1,784,0000.65%
Pier Capital, LLC 294,968$4,401,0000.46%
Navalign, LLC 64,428$961,0000.38%
Gratus Capital, LLC 191,871$2,863,0000.26%
View complete list of ALLOGENE THERAPEUTICS INC shareholders